Imfinzi-Chemo Combo Shows Effectiveness in Treating Triple-negative Breast Cancer, Phase 2 Study Shows

Imfinzi-Chemo Combo Shows Effectiveness in Treating Triple-negative Breast Cancer, Phase 2 Study Shows
The combination of Imfinzi (durvalumab) with standard chemotherapy leads to high treatment effectiveness in patients with triple-negative breast cancer (TNBC), a Phase 2 trial shows. The research, “Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC),” was recently presented at the 2018 ASCO Annual Meeting in Chicago. Imfinzi is a type of immunotherapy called an immune checkpoint inhibitor, which binds to the PD-L1 molecule and blocks its interaction with the PD-1 receptor in immune cells. This mechanism is used by cancer cells to evade immune attacks. The combination of immune checkpoint inhibitors with chemotherapy has led to high response rates in patients with TNBC. This breast cancer type gets its name from the absence of the three most common types of receptors responsible for breast cancer growth: hormone epidermal growth factor receptor 2, estrogen receptors, and progesterone receptors. Researchers conducted the GeparNuevo Phase 2 trial (NCT02685059) to assess the addition of Imfinzi to standard chemotherapy in primary TNBC patients who had not yet received surgery.  A total of
Subscribe or to access all post and page content.